ECO Animal Health Group plc (LON:EAH) Insider David Hallas Acquires 29,897 Shares

ECO Animal Health Group plc (LON:EAH) insider David Hallas purchased 29,897 shares of the business’s stock in a transaction that occurred on Tuesday, July 15th. The shares were purchased at an average price of GBX 67 ($0.90) per share, for a total transaction of £20,030.99 ($26,818.84).

David Hallas also recently made the following trade(s):

• On Friday, April 25th, David Hallas purchased 29,962 shares of ECO Animal Health Group stock. The stock was acquired at an average cost of GBX 67 ($0.90) per share, with a total value of £20,074.54 ($26,877.15).

ECO Animal Health Group Stock Performance

LON:EAH opened at GBX 71 ($0.95) on Wednesday. The company’s 50-day moving average price is GBX 61.57 and its 200-day moving average price is GBX 60.65. The company has a current ratio of 2.96, a quick ratio of 2.14 and a debt-to-equity ratio of 4.81. The company has a market cap of £48.11 million, a P/E ratio of 45.90 and a beta of -0.05. ECO Animal Health Group plc has a twelve month low of GBX 50 ($0.67) and a twelve month high of GBX 126 ($1.69).

ECO Animal Health Group (LON:EAH) last announced its quarterly earnings results on Monday, July 14th. The company reported GBX 2.49 ($0.03) earnings per share for the quarter. ECO Animal Health Group had a net margin of 1.17% and a return on equity of 1.27%.

Analysts Set New Price Targets

Separately, Shore Capital restated a “buy” rating and set a GBX 150 ($2.01) price target on shares of ECO Animal Health Group in a research note on Monday.

About ECO Animal Health Group

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.